Interleukin-23 in perspective

Jonathan P. Sherlock1,2 and Daniel J. Cua1

Key words: IL-23p19-specific inhibitors, psoriasis, biologic therapy, cytokines, psoriatic, tumour necrosis factor inhibitors, psoriatic disease, psoriatic arthritis, biologic, interleukin-23

IL-23 history

IL-23 was discovered 20 years ago in an in silico bioinformatics search for novel members of the IL-6 cytokine family [1]. This immune modulator is a heterodimeric cytokine comprising a p19 subunit linked to a p40 subunit shared with IL-12. Importantly, the same common p40 subunit links to a unique p35 subunit to form IL-12. Because of the shared p40 subunit, much of the pathobiology attributed to IL-12 (1989–2002) was in fact driven by two distinct cytokines, IL-12 and IL-23. The discovery of IL-23 prompted re-examination of immune pathways regulating inflammatory diseases. At that time it was thought that the classical Th1 cell-induced IFN-γ response is required for induction and maintenance of autoimmune inflammation. Historically Th1 cells were thought to promote autoimmunity, principally through studies using p40-deficient mice and p40 neutralizing antibodies. However, there were inconsistencies. As previously reviewed, mice lacking critical components of the Th1–IFN-γ pathway (e.g. IFN-γ−/−, IFN-γR−/−, IL-12Rβ2−/− and IL-12p35−/− mice) are highly susceptible to autoimmune inflammation [2]. When we set out to re-examine the relative contribution of IL-12 vs IL-23, using IL-23-deficient p19−/− mice, p35−/− (IL-12 deficient) and p40−/− (IL-12 and IL-23 deficient) mice, IL-23 was shown to be the critical player in autoimmune inflammation [3]. It was remarkable that the disease-resistant IL-23p19−/− mice developed normal autoantigen-specific Th1 responses, while being severely impaired in the development of IL-17-producing T cells. In contrast, the disease-susceptible p35−/− mice (lacking IL-12) displayed impaired Th1 responses, with greater frequency of IL-17-producing pathogenic Th17 cells.

We recognized in 2004 that IL-23 promoting IL-17 production is linked to multiple human autoimmune disorders [4], including multiple sclerosis [5] and psoriasis [6], suggesting a role for the Th17 pathway in human diseases. IL-17-producing T cells were found in the synovium of Lyme arthritis patients [7], pointing to involvement of IL-17 in infection-induced immunopathology. The IL-17A receptor (IL-17RA), which binds both IL-17A and IL-17F, is commonly expressed in a broad range of cell types, including endothelial cells, skin epithelial cells and gut enterocytes [8]. Activation of IL-17A and/or IL-17F in these cells promotes the expression of IL-1, IL-6, IL-8 and TNF, which perpetuates chronic inflammatory responses. These early studies set the stage for the development of IL-17 and IL-23 inhibitors (IL-17i and IL-23i) approved to treat autoimmune disorders. Today, three IL-17i and four IL-23i agents are approved to treat patients with active PsA.

IL-23 and anatomical pathology

Although initial studies investigating IL-23 biology focussed on antigen-mediated T cell responses, it became apparent that the cytokine plays an important role within a cluster of seronegative T cell responses, which the role of specific antigens is less clear. Of great interest,
these diseases reveal a very strong relationship between IL-23 biology and specific anatomical features. IL-23 not only plays a prominent role at externally facing barrier surfaces, particularly the skin [9] and gut [10], but it also drives inflammation at internal sterile sites such as the joints [11]. While the skin and gut barrier is characterized by the presence of an extensive microbiome, a fundamental feature of the joints is the presence of high biomechanical stress. IL-23-responsive cells appear to specifically localize to these barrier surfaces and structures that transmit biomechanical force. These tissue-resident cells are present even in the healthy state and may have roles in regulating barrier function and tissue repair and maintenance.

Experimental overactivity of the IL-23 pathway within these sites leads to hallmark pathological features of IBD, psoriasis and PsA in mice [9–11]. It is well known that in humans these diseases are closely linked; patients with one disease have an elevated risk of developing another. Further evidence that these conditions constitute a fundamental unity comes from the observation that in patients with one disease, subclinical disease is often present at another anatomical site. Thus patients with IBD or psoriasis are at increased risk of having subclinical enthesitis or sacroiliitis [12, 13]. Patients with enthesiopathic arthritis often have subclinical bowel inflammation, which is associated with elevated production of IL-23 in the gut [14]. Intestinal dysbiosis not only occurs in IBD, but also in PsA [15]. All of these conditions are associated with uveitis, and patients with apparently isolated uveitis not only have a tendency for subclinical bowel inflammation [16], but also extensive subclinical enthesitis [17]. Such unifying clinical observations are further supported by shared genetic components, many of which are in the IL-23 pathway and include IL-23R and Tyk2.

IL-23 can induce inflammation in the gut, skin and joints in a remarkably efficient manner. Indeed, IL-23 alone can directly, rapidly and reproducibly induce the hallmark clinical features of human psoriasis [9] and PsA in mice [11]. While mucosal immunology is much more complex and IL-23 is produced in the gut in the healthy state, recent work has shown that IL-23 expression in the gut in combination with other perturbations can induce relapsing–remitting gut inflammation [18].

IL-23R is constitutively expressed on natural killer (NK) cells, innate lymphoid cells, γδ T cells and mucosal-associated invariant T (MAIT) cells, all of which recognize structural elements via invariant T cell receptor or other recognition motifs. Engagement of IL-23R activates a range of Janus kinases (JAKs) and signal transducers and activators of transcription (STATs), including JAK2, tyrosine kinase 2 (TYK2) and STAT3, STAT4 and STAT5, with TYK2 and STAT3 being the dominant drivers of Th17 immune-pathway signature genes. The ability of IL-23 to act rapidly on barrier tissues is particularly interesting since the rapid responsiveness of these anatomical tissues is due to the presence of resident type 17 cells, which already express IL-23R. Isolated entheses from both mice [11] and humans [19] have small numbers of IL-23-responsive cells. The pattern of tissue localization of IL-23R thus determines the clinical anatomical structures that become inflamed when IL-23 biology is dysregulated. This is particularly marked in the joints, where the IL-23R+ cells localize to tensile fibres at ‘entheseal’ insertions of tendons or ligaments to bone. Thus IL-23 expression induces enthesitis in mice along with multiple features of human enthesiopathic arthritis, such as periostitis and enthesal and perioseal new bone formation and bone erosion in the absence of an initial synovitis. Later, a ‘secondary’ synovitis develops, which is highly destructive and reminiscent of PsA mutilans [11]. This pattern of disease is strikingly different from RA in which a seropositive response drives a primary synovitis without a crucial role for IL-23.

**IL-23 in the clinic**

Today, clinical evaluation of IL-17 and IL-23 inhibitors has corroborated the initial thinking that the IL-23–Th17 pathway can promote many barrier and ‘high-stress tissue’–associated immune diseases. Studies are showing clinical benefits for skin, joint and gastrointestinal tissue inflammation. Both the IL-17 class and IL-23 class of agents are effective for psoriasis, including secukinumab and ixekizumab (anti-IL-17A), brodalumab (anti-IL-17RA) and tirikuzumab, risankizumab and guselkumab (anti-IL-23p19). Currently secukinumab, ixekizumab and guselkumab are also approved to treat PsA. Importantly, long-term clinical trial data have shown that >80% of patients maintained a durable response of >90% skin clearance and more than half of the patients maintained a durable response with complete skin clearance [20].

The anti-IL-12/23p40 agent ustekinumab is also approved to treat ulcerative colitis and Crohn’s disease, and emerging data from phase 2 studies have indicated that the anti-IL-23p19 agents guselkumab, mirikizumab and risankizumab are effective and safe in patients with these conditions [21–23]. Pivotal registrational studies for all three IL-23is are ongoing in these indications.

The progression of immunological thought is at an inflection point. Molecular and cellular immunology combined with new ways of aggregating and utilizing large clinical data sets are transforming research ideas into new medicines for diseases thought intractable only a few years ago. One of the major challenges ahead is to test novel concepts targeting a broad range of rare disease indications of the skin, eye, central nervous system, blood vessels and endocrine glands. To block the entire Th17 pathway, a drug must target IL-23R+ tissue resident cells (often behind the blood–tissue barrier) as well as migrating cell populations that engage IL-23 and become reprogrammed to promote inflammation. These same cells are the drivers of chronic injury responses, which are responsible for many autoimmune diseases. There remains much work to be done. Achieving even greater frequency of complete and durable clinical remission is the new goal in immunology trials. We eagerly
anticipate new treatment strategies that will change the lives of patients.

Funding: This paper was published as part of a supplement sponsored by the Janssen Pharmaceutical Companies of Johnson & Johnson.

Disclosure statement: J.S. and D.C. are employees of Janssen Research & Development.

Data availability statement
Data are provided in the article.

References
1 Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715–25.
2 Sherlock JP, Zúñiga LA, Cua DJ. IL-23 in health and disease. In: T Yoshimoto, T, Yoshimoto, eds. Cytokine frontiers: regulation of immune responses in health and disease. Tokyo: Springer, 2014:179–98.
3 Cua DJ, Sherlock, J Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421:744–8.
4 Langrish CL, McKenzie BS, Wilson NJ et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004;202:96–105.
5 Matsu sevicius D, Kivisääk P, He B et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101–4.
6 Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111:645–9.
7 Infante-Duarte C, Horton HF, Byrne MC, Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 2000;165:610–7.
8 Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009;9:556–67; erratum: Nat Rev Immunol 2009;9:747.
9 Chan JR, Blumenschein W, Murphy E et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577–87.
10 Yen D, Cheung J, Scheerens H et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006;116:1310–6.
11 Sherlock JP, Joyce-Shaikh B, Turner SP et al. IL-23 induces spondylarthropathy by acting on ROR-γt+ CD3+CD4+CD8− entheseal resident T cells. Nat Med 2012;18:1069–76.
12 Ahmed MM, Elolemy GG, Alfeeli AK, Baqer AB, Gad AM. Ultrasonographic enthesisopathy and disease activity in psoriatic arthritis. Open Access Maced J Med Sci 2017;5:651–6.
13 Kelly OB, Li N, Smith M et al. The prevalence and clinical associations of subclinical sacroiliitis in inflammatory bowel disease. Inflamm Bowel Dis 2019;25:1066–71.
14 Ciccia F, Bombardieri M, Principato A et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 2009;60:955–65.
15 Scher JU, Ubeda C, Artacho A et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol 2015;67:128–39.
16 Bañeres AA, Jover JA, Fernández-Gutiérrez B et al. Bowel inflammation in anterior uveitis and spondyloarthropathy. J Rheumatol 1995;22:1112–7.
17 Muñoz-Fernández S, de Miguel E, Cobo-Ibáñez T et al. Enthesitis inflammation in recurrent acute anterior uveitis without spondylarthritis. Arthritis Rheum 2009;60:1985–90.
18 Chen L, He Z, Iuga AC et al. Diet modifies colonic microbiota and CD4+ T-cell repertoire to induce flares of colitis in mice with myeloid-cell expression of interleukin 23. Gastroenterology 2018;155:1177–91.e16.
19 Wata d A, Rowe H, Russell T et al. Normal human enthesis harbourns conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression. Ann Rheum Dis 2020;79:1044–54.
20 Griffiths C, Papp KA, Song M et al. Maintenance of response through 5 years of continuous guselkumab treatment: results from the phase 3 VOYAGE 1 trial. Presented at the Coastal Dermatology Symposium Virtual Meeting Experience, 15–16 October 2020.
21 Sandborn WJ, Chan D, Johanns J et al. The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Crohn’s disease: week 12 interim analyses from the phase 2 GALAXI 1 study (abstract OP089). Presented at the United European Gastroenterology Week Virtual Congress, 11–13 October 2020.
22 Sandborn WJ, Ferrante M, Bhandari BR et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology 2020;158:537–49.e10.
23 Feagan BG, Sandborn WJ, D’Haens G et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2017;389:1699–709.